These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 23295945)

  • 1. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleeping beauty system to redirect T-cell specificity for human applications.
    Maiti SN; Huls H; Singh H; Dawson M; Figliola M; Olivares S; Rao P; Zhao YJ; Multani A; Yang G; Zhang L; Crossland D; Ang S; Torikai H; Rabinovich B; Lee DA; Kebriaei P; Hackett P; Champlin RE; Cooper LJ
    J Immunother; 2013 Feb; 36(2):112-23. PubMed ID: 23377665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
    Huls MH; Figliola MJ; Dawson MJ; Olivares S; Kebriaei P; Shpall EJ; Champlin RE; Singh H; Cooper LJ
    J Vis Exp; 2013 Feb; (72):e50070. PubMed ID: 23407473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
    Kim M; Kim H; Han M; Hwang HJ; Kim H; Im HJ; Kim N; Koh KN
    Anticancer Res; 2021 Dec; 41(12):6031-6038. PubMed ID: 34848457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
    Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
    Singh H; Huls H; Kebriaei P; Cooper LJ
    Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
    Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
    Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.
    Jin Z; Maiti S; Huls H; Singh H; Olivares S; Mátés L; Izsvák Z; Ivics Z; Lee DA; Champlin RE; Cooper LJ
    Gene Ther; 2011 Sep; 18(9):849-56. PubMed ID: 21451576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
    Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
    J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.